MabSpace Biosciences specializes in discovery and early development of antibody-based therapeutics, emphasizing cancer treatments. Its core platform is a proprietary immune tolerance breaking technology and translational science platform designed to generate candidate antibodies that bind different epitopes and display differentiated properties versus benchmark antibodies. The company aims to discover novel antibodies targeting components of the tumor microenvironment to enhance responses in tumors less likely to respond to T cell checkpoint monotherapy. MabSpace plans to advance multiple therapeutic programs into human clinical proof-of-concept studies. It is headquartered in Suzhou with a fully integrated antibody discovery and development facility in Biobay, Suzhou Industrial Park. Company leadership includes Founder, Chairman and CEO Dr. Xueming Qian.

Total raised

$15M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2015